Published on February 23, 2021

Just days after being granted FastTrack status by the U.S. Food and Drug Administration, Targovax released the latest clinical data for ONCOS-102, revealing continued overall survival that has not yet reached an apparent median point.

Targovax | LinkedIn

ONCOS-102 Combination with Chemotherapy Shows Continued Promise

This morning, Targovax released the 21-month follow-up data from its randomized phase I/II trial of ONCOS-102 in combination with chemotherapy for the treatment of malignant pleural mesothelioma, and the results have been extremely promising. The study included 31 patients, 20 of whom were treated with a combination of ONCOS-102 and pemetrexed/cisplatin and the other 11 of whom received only chemotherapy. 

At the 21-month mark, half of the mesothelioma patients who received the combination treatment being studied are still alive, indicating that median overall survival is not yet known but will be at least 20.5 months. By comparison, of the 11 patients in the group that received chemotherapy alone, the median overall survival has been determined to be 13.5 months, revealing a highly significant improvement, the extent of which is still not fully realized.

Researchers Praise “Profound” Results

Speaking of the results seen thus far in the mesothelioma trial, Dr. Magnus Jäderberg, Chief Medical Officer of Targovax, said, “It is most encouraging that survival continues to track so well in the ONCOS-102-treated first line group. We have earlier seen and reported how ONCOS-102 drives profound remodeling of the tumor microenvironment. It is now becoming clear that this is translating into long-term survival benefit. The survival data also holds up well to the recently FDA-approved ipilimumab and nivolumab combination, confirming the relevance of immunotherapy in mesothelioma and strongly suggesting combining ONCOS-102 with checkpoint inhibition could further boost efficacy in this highly malignant and difficult-to-treat cancer.”

If you or someone you love has been diagnosed with malignant mesothelioma, immunotherapy treatments may be available to you through clinical trials and other sources. For information on how to access these resources, contact the Patient Advocates at Mesothelioma.net today at 1-800-692-8608.

Written by Terri Oppenheimer

Terri Heimann Oppenheimer
Terri Heimann Oppenheimer is the head writer of our Mesothelioma.net news blog. She graduated from the College of William and Mary with a degree in English. Terri believes that knowledge is power and she is committed to sharing news about the impact of mesothelioma, the latest research and medical breakthroughs, and victims’ stories.

Learn more about and contact Terri

Leave a Reply

Your email address will not be published. Required fields are marked *